Matinas BioPharma Hldgs Stock (AMEX:MTNB), Analyst Ratings, Price Targets, Predictions

The latest price target for Matinas BioPharma Hldgs (AMEX: MTNB) was reported by BTIG on October 11, 2023. The analyst firm set a price target for $3.00 expecting MTNB to rise to within 12 months (a possible 1581.61% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Matinas BioPharma Hldgs (AMEX: MTNB) was provided by BTIG, and Matinas BioPharma Hldgs their buy rating.

There is no last upgrade for Matinas BioPharma Hldgs.

There is no last downgrade for Matinas BioPharma Hldgs.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Matinas BioPharma Hldgs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Matinas BioPharma Hldgs was filed on October 11, 2023 so you should expect the next rating to be made available sometime around October 11, 2024.

While ratings are subjective and will change, the latest Matinas BioPharma Hldgs (MTNB) rating was a with a price target of $3.00 to $3.00. The current price Matinas BioPharma Hldgs (MTNB) is trading at is $0.18, which is out of the analyst’s predicted range.